Suramin Is an Active Site-directed, Reversible, and Tight-binding Inhibitor of Protein-tyrosine Phosphatases

Yanling Zhang, Yen‐Fang Keng, Yu Zhao, Li Wu, Zhong‐Yin Zhang

Journal of Biological Chemistry · 1998 · 113 citations · 51 references

DOIFull text

Open access

Concepts

Abstract

The effect of suramin, a well known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers, on protein-tyrosine phosphatases (PTPases) has been examined. Suramin is a reversible and competitive PTPase inhibitor withK is values in the low μm range, whereas the K is for the dual specificity phosphatase VHR is at least 10-fold higher. Although suramin can also inhibit the activity of the potato acid phosphatase at a slightly higher concentration, it is 2–3 orders of magnitude less effective against the protein Ser/Thr phosphatase 1α and the bovine intestinal alkaline phosphatase. Suramin binds to the active site of PTPases with a binding stoichiometry of 1:1. Furthermore, when suramin is bound to the active site of PTPases, its fluorescence is enhanced approximately by 10-fold. This property has allowed the determination of the binding affinity of suramin for PTPases and several catalytically impaired mutant PTPases by fluorescence titration techniques. Thus, the active site Cys to Ser mutants bind suramin with similar affinity as the wild type, while the active site Arg to Ala mutant exhibits a 20-fold reduced affinity toward suramin. Interestingly, the general acid deficient Asp to Ala mutant PTPases display an enhanced affinity toward suramin, which is in accord with their use as improved “substrate-trapping” agents. That suramin is a high affinity PTPase inhibitor is consistent with the observation that suramin treatment of cancer cell lines leads to an increase in tyrosine phosphorylation of several cellular proteins. Given the pleiotropic effects of suramin on many enzyme systems and growth factor-receptor interactions, the exact in vivo actions of suramin require further detailed structure-activity investigation of suramin and its structural analogs. The effect of suramin, a well known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers, on protein-tyrosine phosphatases (PTPases) has been examined. Suramin is a reversible and competitive PTPase inhibitor withK is values in the low μm range, whereas the K is for the dual specificity phosphatase VHR is at least 10-fold higher. Although suramin can also inhibit the activity of the potato acid phosphatase at a slightly higher concentration, it is 2–3 orders of magnitude less effective against the protein Ser/Thr phosphatase 1α and the bovine intestinal alkaline phosphatase. Suramin binds to the active site of PTPases with a binding stoichiometry of 1:1. Furthermore, when suramin is bound to the active site of PTPases, its fluorescence is enhanced approximately by 10-fold. This property has allowed the determination of the binding affinity of suramin for PTPases and several catalytically impaired mutant PTPases by fluorescence titration techniques. Thus, the active site Cys to Ser mutants bind suramin with similar affinity as the wild type, while the active site Arg to Ala mutant exhibits a 20-fold reduced affinity toward suramin. Interestingly, the general acid deficient Asp to Ala mutant PTPases display an enhanced affinity toward suramin, which is in accord with their use as improved “substrate-trapping” agents. That suramin is a high affinity PTPase inhibitor is consistent with the observation that suramin treatment of cancer cell lines leads to an increase in tyrosine phosphorylation of several cellular proteins. Given the pleiotropic effects of suramin on many enzyme systems and growth factor-receptor interactions, the exact in vivo actions of suramin require further detailed structure-activity investigation of suramin and its structural analogs. Suramin is a polysulfonated naphthylurea compound (see Fig.1 A) that has been widely used for the treatment of trypanosomiasis (sleeping sickness) and onchocerciasis since the early 1920s (1Hawking F. Adv. Pharmacol. Chemother. 1978; 15: 289-322Crossref PubMed Scopus (255) Google Scholar). It was originally synthesized by Bayer AG in 1916 based on the observation that trypan red and trypan blue exhibited trypanocidal activity (2Dressel J. Oesper R.E J. Chem. Educ. 1961; 38: 620-621Crossref Scopus (27) Google Scholar, 3La Rocca R.V. Stein C.A. Danesi R. Myers C.E. J. Steroid Biochem. Mol. Biol. 1990; 37: 893-898Crossref PubMed Scopus (55) Google Scholar). Since the last decade, many new and therapeutically significant properties of this compound have been identified. For example, suramin has been shown to prevent the infection of T lymphocytes by human immunodeficiency virus in vitro (4Mitsuya M. Popovic M. Yarchoan R. Matsushita S. Gallo R.C. Broder S. Science. 1984; 226: 172-174Crossref PubMed Scopus (321) Google Scholar). Suramin has also been shown to exert antiproliferative activities by interfering with the binding of a number of growth factors, such as platelet-derived growth factor, epidermal growth factor, basic fibroblast growth factor, transforming growth factor-β (5Williams L.T. Tremble P.M. Lavin M.F. Sunday M.E. J. Biol. Chem. 1984; 259: 5287-5294Abstract Full Text PDF PubMed Google Scholar, 6Hosang M. J. Cell. Biochem. 1985; 29: 265-273Crossref PubMed Scopus (231) Google Scholar, 7Betsholtz C. Johnsson A. Heldin C.-H. Westermark B. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 6440-6444Crossref PubMed Scopus (231) Google Scholar, 8Coffey R.J. Leof E.B. Shipley G.D. Moses H.L. J. Cell. Physiol. 1987; 132: 143-148Crossref PubMed Scopus (344) Google Scholar, 9Presta M. Tiberio L. Rusnati M. Dell'Era P. Ragnotti G. Cell Regul. 1991; 2: 719-726Crossref PubMed Scopus (59) Google Scholar), and tumor necrosis factor-α (10Alzani R. Cozzi E. Corti A. Temponi M. Trizio D. Gigli M. Rizzo V. Biochemistry. 1995; 34: 6344-6350Crossref PubMed Scopus (28) Google Scholar) to their corresponding receptors. The ability of suramin to block the activity of several growth factors that play important role in tumor cell biology has prompted studies directed at the use of suramin as an antineoplastic agent (3La Rocca R.V. Stein C.A. Danesi R. Myers C.E. J. Steroid Biochem. Mol. Biol. 1990; 37: 893-898Crossref PubMed Scopus (55) Google Scholar). Indeed, subsequent investigations have shown that suramin exhibits antitumor activity against several metastatic cancers such as renal cancer, adrenocarcinoma, lymphoma, and prostate cancer (11Stein C.A. LaRocca R.V. Thomas R. McAtee N. Myers C.E. J. Clin. Oncol. 1989; 7: 499-508Crossref PubMed Scopus (344) Google Scholar, 12Stein C.A. Cancer Res. 1993; 53: 2239-2248PubMed Google Scholar). If the antitumor property of suramin is solely due to its ability to antagonize the activity of growth factors that stimulate the intrinsic protein-tyrosine kinase activity of the receptors, one would expect a decrease in tyrosine phosphorylation in cancer cells upon exposure to suramin. Unexpectedly, suramin treatment of epidermal carcinoma and several prostate, breast, gastric, and colon cancer cell lines causes rapid and dramatic increase in tyrosine phosphorylation of several cellular proteins (13Sartor O. McLellan C.A. Myers C.E. Borner M.M. J. Clin. Invest. 1992; 90: 2166-2174Crossref PubMed Scopus (18) Google Scholar, 14Cardinali M. Sartor O. Robbins K.C. J. Clin. Invest. 1992; 89: 1242-1247Crossref PubMed Scopus (44) Google Scholar). These observations cast doubt about the notion that the antitumor action of suramin simply arises from abrogation of growth factor functions and suggest the possibility that suramin may suppress cell growth by altering directly the enzymatic activity of protein-tyrosine kinases and protein-tyrosine phosphatases (PTPases). 1The abbreviations used are: PTPase, protein-tyrosine phosphatases; pNPP,p-nitrophenyl phosphate. PTPases, in conjunction with protein-tyrosine kinases, control the state of tyrosine phosphorylation in cellular proteins, which regulate a wide variety of biological processes such as cell growth, differentiation and oncogenic transformation (15Hunter T. Biochem. Soc. Trans. 1996; 24: 307-327Crossref PubMed Scopus (80) Google Scholar, 16Neel B.G. Tonks N.K. Curr. Opin. Cell Biol. 1997; 9: 193-204Crossref PubMed Scopus (743) Google Scholar). Although suramin is capable of reducing the activity of Ser/Thr kinases such as protein kinase C (17Hensey C.E. Boscoboinik D. Azzi A. FEBS Lett. 1989; 258: 156-158Crossref PubMed Scopus (97) Google Scholar,18Mahoney C.W. Azzi A. Huang K.P. J. Biol. Chem. 1990; 265: 5424-5428Abstract Full Text PDF PubMed Google Scholar) and Cdc2 (19Bojanowski K. Nishio K. Fukuda M. Larsen A.K. Saijo N. Biochem. Biophys. Res. Commun. 1994; 203: 1574-1580Crossref PubMed Scopus (23) Google Scholar), the effect of suramin on protein-tyrosine kinase activity is unknown. Interestingly, suramin has also been reported to enhance the tyrosine phosphorylation of Cdc2 kinase in a nuclear extract (19Bojanowski K. Nishio K. Fukuda M. Larsen A.K. Saijo N. Biochem. Biophys. Res. Commun. 1994; 203: 1574-1580Crossref PubMed Scopus (23) Google Scholar) and to inhibit the tyrosine phosphatase activity of a preparation of immunoprecipitated plasma membrane bound CD45 in a noncompetitive and irreversible manner (20Ghosh J. Miller R.A. Biochem. Biophys. Res. Commun. 1993; 194: 36-44Crossref PubMed Scopus (27) Google Scholar). Given the structural and chemical nature of suramin (Fig.1 A), we were intrigued by the observation that suramin inhibits the CD45 phosphatase activity noncompetitively and irreversibly. Suramin lacks a reactive functionality and possesses six sulfonic acid groups attached directly to aromatic rings. Thus, it is possible that suramin may bind the PTPase active site, which recognize phosphotyrosine (21Jia Z. Barford D. Flint A.J. Tonks N.K. Science. 1995; 268: 1754-1758Crossref PubMed Scopus (565) Google Scholar), and acts as a competitive, reversible PTPase This possibility with the observation that suramin the tyrosine phosphorylation of several proteins in tumor cells and in Cdc2 prompted to detailed and binding studies on PTPase, the and several active mutant PTPases in to the of action of suramin on Furthermore, we have also the effect of suramin on the by the dual specificity phosphatase the protein Ser/Thr phosphatase the potato acid and the bovine intestinal alkaline phosphatase. were from and used further was from Suramin was a from at the Cancer acid was from were and phosphatase and alkaline phosphatase were from phosphatase 1α was a from at the of was from and from U. S. The of PTPase H.L. J. Biol. Chem. 1992; Full Text PDF PubMed Google Scholar), M. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar), and the dual specificity phosphatase VHR L. L. Biochemistry. 1995; 34: PubMed Scopus Google Scholar) were used in this The of the PTPase and were from the corresponding and were the used in structural studies D. Flint A.J. Tonks N.K. Science. 1994; PubMed Scopus Google Scholar, E.B. 1994; PubMed Scopus Google Scholar). The PTPase, and VHR were in and to as H.L. J. Biol. Chem. 1992; Full Text PDF PubMed Google Scholar, M. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar, L. L. Biochemistry. 1995; 34: PubMed Scopus Google Scholar). was from at an of for PTPase, for and for that in the PTPase to an Ala and in to an Ala were the in from The used were as and the the from the were by The L. Biochemistry. 1997; PubMed Scopus Google Scholar), L. E.B. H.L. Biochemistry. 1994; PubMed Scopus Google Scholar), and M. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar) have been of the mutant PTPases were similar to for the wild The PTPase activity was at in a an of as The with of by The was by of the enzyme and 2–3 by of of The of the was by the control the of the The was from the at a of The of suramin were for the and VHR in the of suramin, the at was as J. Biol. Chem. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar). The was to to the The effects of suramin on phosphatases were also at as a For potato acid the was in For bovine intestinal alkaline the was in For protein phosphatase the was in with a cell was used for suramin fluorescence The μm suramin and of PTPase in A. from were with an of at of μm suramin in was in the at as the of PTPase was and with the suramin The protein was The of suramin binding to the PTPase was by the increase in fluorescence at with an of the of suramin and the PTPase were at μm while the of suramin to the PTPase The fluorescence of the was as a of the of suramin to the PTPase at in A. The fluorescence was when the of suramin to protein to the stoichiometry of the the of suramin binding to PTPases, the were PTPase and suramin was at in for and its fluorescence was a of the enzyme was also for activity a of suramin was to the that the for suramin and the PTPase was and The fluorescence of this was and with the which was by directly to μm the affinity of suramin to the PTPases, the fluorescence of the bound suramin was as of the PTPases was to a of suramin at in A. The was and the fluorescence was at The of suramin and the proteins at and was less in the used for the The K was by a of the to is the the fluorescence of and the fluorescence of the were used a to the control of suramin with the of and the control of the with the protein a which is the the fluorescence of bound suramin and of suramin and protein the and is of the in the and is the of the is the protein of and the suramin in the was to the of suramin and the PTPase Suramin fluorescence of this was and with the fluorescence of the in of of the were and were in of were at least with similar The for is and the shown as the state for the by the PTPase, and the dual specificity phosphatase as a at and PTPases an Asp in and in the as a general to Proc. Natl. Acad. Sci. U. S. A. 1994; PubMed Scopus Google Scholar, L. Biochemistry. 1995; 34: PubMed Scopus Google Scholar, L. Biochemistry. 1996; PubMed Scopus Google Scholar, N. Biochemistry. 1997; PubMed Scopus Google Scholar). of in in the PTPase by an Ala reduced the by and Interestingly, of in in PTPase with an Ala improved for by and of the PTPase is a in the PTPase L. E.B. H.L. Biochemistry. 1994; PubMed Scopus Google Scholar). The in a with the of the E.B. 1994; PubMed Scopus Google Scholar) and is in binding and L. E.B. H.L. Biochemistry. 1994; PubMed Scopus Google Scholar). The K of the PTPase by 20-fold while was reduced by of PTPases with as a at in a new have the ability of suramin to inhibit the action of PTPases and the of by suramin at shown in the effect of suramin on the the for competitive were for the PTPase and the dual specificity phosphatase Thus, suramin acts as a competitive inhibitor for the PTPase and The competitive is the structural of in suramin with The K is values for suramin with PTPase and and while the K is for suramin with VHR is which is for the PTPase and also the ability of a sulfonic acid acid (Fig.1 to inhibit acid the PTPase activity with is of of suramin toward PTPases at by by fluorescence titration by by fluorescence titration by by by fluorescence titration in a new the by suramin on PTPases this we have the effect of suramin on by potato acid bovine intestinal alkaline and protein Ser/Thr phosphatase Suramin the potato acid and the of was with K is μm and K The of for suramin in the protein phosphatase was also in this K is μm and K Interestingly, suramin as a competitive inhibitor for the alkaline with is of suramin a low fluorescence when at M. J. A. M. M. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). The fluorescence of suramin in the of of a increase in the at the fluorescence whereas the of suramin fluorescence of suramin titration with observation has been when were to a suramin M. J. A. M. M. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). The increase in fluorescence at in the at high was due to the intrinsic fluorescence of which at the fluorescence titration the from the protein to the fluorescence was by (see observations were also for the PTPase and The fluorescence was 10-fold for at the and enzyme of and a fluorescence of suramin upon the binding of PTPase can used to the affinity of suramin for PTPases of fluorescence PTPase that suramin is a high affinity inhibitor for and the to the binding by fluorescence a and reversible binding is The fluorescence of suramin was was to suramin, its fluorescence and of its was the for the The fluorescence and the in similar was upon suramin binding to These that suramin binding to PTPases is a the of the binding of suramin to the PTPases, the phosphatase activity and suramin fluorescence of the PTPases were with of PTPases from the suramin bound was with an of suramin, which in of in the was based on is of suramin of μm for the was by of in the The fluorescence of the μm suramin and μm is shown in Suramin fluorescence when μm of suramin was to the and suramin the fluorescence and to the as the control which was of and suramin This that from the has the and is to bind suramin This is by of the phosphatase activity of from the the and suramin was 10-fold further for activity the enzyme activity of this was to the as the in the of suramin. This that from the enzymatic were also with the Thus, the suramin and PTPases rapid and Suramin fluorescence when it binds to the stoichiometry of suramin binding to PTPases, the of the fluorescence of the on the of suramin to the protein was while the of suramin and the protein that suramin fluorescence to the at a suramin to of 1:1. stoichiometry of was also for suramin binding to the VHR and of the mutants PTPases and These that PTPases and their mutants one binding site for suramin. Since suramin competitive against PTPases, it is important to the suramin binding site on the PTPases to the PTPase active site phosphotyrosine binding is a well known competitive inhibitor of PTPases and the of PTPase with that binds at the active site J. Proc. Natl. Acad. Sci. U. S. A. 1996; PubMed Scopus Google Scholar). of was to the suramin and in the suramin fluorescence in The for the ability of to suppress binding of suramin to the active site of is shown in the of These that was to suramin from the active site of observation was also for Furthermore, an active site mutant PTPase with affinity for and also a reduced binding toward suramin (see of the suggest that suramin, binds at the active site of have shown that suramin binds to the active site of PTPases and The suramin exhibits enhanced fluorescence at when at These properties have allowed to the suramin binding for PTPase and several of the active mutants PTPases with low fluorescence titration for the determination of binding of suramin to is shown in the of The was by a least of the titration to the binding as The for suramin binding to the PTPase, and the mutants in The K values by fluorescence titration for and PTPase were and which were similar to the by state The in the fluorescence titration and by the in experimental such as enzyme The general acid deficient mutant PTPases and the active site Arg mutant display low phosphatase Furthermore, the active site Cys to Ser mutant PTPases phosphatase activity at L. Biochemistry. 1997; PubMed Scopus Google Scholar). Thus, of the affinity of suramin toward mutant PTPases by enzyme can The fluorescence titration is an to suramin binding for low activity PTPase Interestingly, higher affinity the wild enzyme toward suramin. of in and in the PTPase by a Ser the affinity for suramin, the phosphatase activity was The of in the PTPase with in the of a an E.B. 1994; PubMed Scopus Google Scholar). of by an Ala in the PTPase has been shown to decrease the affinity of the PTPase and competitive by and L. E.B. H.L. Biochemistry. 1994; PubMed Scopus Google Scholar). we that of by an Ala in the PTPase also in a 20-fold decrease in the affinity toward suramin. These suggest that the active site Arg with the on the of suramin in the manner as it with the on the and is consistent with the that suramin binds the PTPase active have the effect of suramin on PTPases, human and the PTPase, of which have been and Curr. Cell. Regul. 1997; PubMed Scopus Google Scholar). in the PTPase is a of dual specificity phosphatases that can the of phosphotyrosine also S. 1991; PubMed Scopus Google Scholar). The effect of suramin on the human dual specificity phosphatase the of this of is also a variety of and fluorescence titration we that suramin is a high affinity PTPase we that the of suramin is competitive and that the binding of suramin to the PTPases and VHR is rapid and we that the binding stoichiometry of suramin to PTPases is and suramin binds directly to the active site of the PTPases and These in to a that suramin inhibits the phosphatase activity of the PTPase CD45 noncompetitively and (20Ghosh J. Miller R.A. Biochem. Biophys. Res. Commun. 1993; 194: 36-44Crossref PubMed Scopus (27) Google Scholar). the for this in the early an immunoprecipitated plasma CD45 preparation was while in PTPases were Although the acid of the PTPase is to it is that their a structural with in D. Flint A.J. Tonks N.K. Science. 1994; PubMed Scopus Google Scholar, E.B. 1994; PubMed Scopus Google Scholar). the of the PTPases in and the it is that and the PTPase bind suramin with similar The dual specificity phosphatases with the PTPases, in the of the active site binding The of the dual specificity phosphatase VHR a general that in the PTPases, which many of the and structural of PTPases J. Science. 1996; PubMed Scopus Google Scholar). It that the dual specificity phosphatases and the PTPases also a chemical for Curr. Cell. Regul. 1997; PubMed Scopus Google Scholar). Interestingly, the affinity of VHR for suramin is of the the suramin a affinity for PTPases, we also the ability of suramin to by the acid and alkaline phosphatases as well as protein phosphatase the for activity suramin inhibits the potato acid with higher of the PTPases, whereas suramin is an effective inhibitor for protein phosphatase 1α and alkaline with and orders of magnitude higher of the it that suramin inhibit phosphatases have also that acid is a competitive inhibitor for the the affinity of acid for the PTPase is that of suramin. This that structural in to the in suramin for high affinity It is known that the phosphotyrosine binding site active of possesses significant that a can also B. S. Z. L. Barford D. Biochemistry. 1996; PubMed Scopus Google Scholar). Thus, the may for the enhanced affinity of suramin for It is possible that the in suramin also important for the high affinity suramin is bound to the active site of PTPases, its fluorescence is enhanced approximately 10-fold. This property suramin a to the binding for the catalytically impaired PTPase The active site Cys in PTPases acts as a to the on the J. Biol. Chem. 1991; Full Text PDF PubMed Google Scholar, R. E. J. Chem. Soc. 1992; Scopus Google Scholar). Although the Cys with a Ser the PTPase activity L. Biochemistry. 1997; PubMed Scopus Google Scholar), the mutant protein can bind G. D. A. T. J. Biol. Chem. 1993; 268: Full Text PDF PubMed Google Scholar, Tonks N.K. Cell. 1993; Full Text PDF PubMed Scopus Google Scholar, J. 1997; PubMed Scopus Google Scholar). with that and similar affinity for suramin as the wild of the of in the a important for the binding of the in a the affinity of the PTPase for suramin by which is consistent with the that suramin binds to the PTPase active the Asp is to an the phosphatase activity of the general PTPases is reduced Interestingly, the affinity of and for and suramin by This is consistent with the observation that the general mutant PTPase is a “substrate-trapping” is the active site Cys to Ser mutant for the of PTPase vivo T. Barford D. Tonks N.K. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar). Suramin is in and for the treatment of prostate cancer and It is that the effects of suramin treatment from its ability to block the activity of a number of growth The of suramin for effect was and plasma suramin C.A. Cancer Res. 1993; 53: 2239-2248PubMed Google Scholar). This of suramin is orders of magnitude higher that to the in vitro activity of PTPases, which play important in processes by growth This the therapeutically effective suramin and the to inhibit vitro may for the It is known that suramin is bound to plasma proteins such as Yarchoan R. Broder S. Myers C.E. J. Clin. 1986; PubMed Scopus Google Scholar, J. Biochem. Pharmacol. 1990; PubMed Scopus Google Scholar), which may the effective suramin in Furthermore, of its suramin is membrane and has to cells C.A. Cancer Res. 1993; 53: 2239-2248PubMed Google Scholar). Thus, the of suramin the cell may well the suramin in the It is possible that the increase in tyrosine phosphorylation in cellular proteins and of the effects by suramin treatment may from the of to the growth factors and PTPases, suramin also pleiotropic effects on a variety of enzyme For example, the and suramin can inhibit the activity of protein kinase C (17Hensey C.E. Boscoboinik D. Azzi A. FEBS Lett. 1989; 258: 156-158Crossref PubMed Scopus (97) Google Scholar, C.W. Azzi A. Huang K.P. J. Biol. Chem. 1990; 265: 5424-5428Abstract Full Text PDF PubMed Google Scholar) Cdc2 (19Bojanowski K. Nishio K. Fukuda M. Larsen A.K. Saijo N. Biochem. Biophys. Res. Commun. 1994; 203: 1574-1580Crossref PubMed Scopus (23) Google Scholar), kinase and kinase R. A. Cancer Res. 1990; Google Scholar), and K. J. M. J. Biochem. Scopus Google Scholar, C. R. J. Cancer Res. 1990; Google Scholar), E. Cancer Lett. PubMed Scopus Google Scholar), K. S. J. J. A. Larsen A.K. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: PubMed Scopus Google Scholar), M.F. A.K. 1995; PubMed Scopus Google Scholar), N. FEBS Lett. PubMed Scopus Google Scholar), and M. J. A. M. M. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). a detailed of the effects of suramin in vivo and which of effects important for the antitumor activity further structure-activity studies of suramin and its structural analogs.

References

51